Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma 1Leukemia 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Burkitt Lymphoma 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 15Cisplatin 15pembrolizumab 9Oxaliplatin 7durvalumab 5Leucovorin 5Fluorouracil 5130-nm albumin-bound paclitaxel 5Platinum 4Albumin-Bound Paclitaxel 41,2-diaminocyclohexaneplatinum II citrate 4Trastuzumab 3Taxes 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Capecitabine 3zanidatamab 2fludarabine 2Paclitaxel 2Nivolumab 2Folfox protocol 2Docetaxel 2Cyclophosphamide 2Biopsy 2tucatinib 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tivozanib 1pertuzumab 1peposertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gallbladder Neoplasms × devimistat × 1 year × Clear all
NCT04203160 2025-12-31

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

University of Michigan Rogel Cancer Center

Phase 1/2 Terminated
75 enrolled 17 charts
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡